|
|
|
|
||
Zack's Does ADXSMisses here and there but what can you expect? The Phase I safety and efficacy data from the combination of ADXS-HER2 with radiation in canine osteosarcoma supports further clinical development of ADXS-HER2 in HER2 expressing cancers, such as osteosarcoma, breast, gastric and esophageal cancers. Why did Zack's overlook HER2/NEU-expressing pancreatic cancer? This is an aging listing of likely antigens for treating pancreatic cancer. HER2/NEU is shown as overexpressed in greater than 50% of the cancer. ADRO's GVAX targeted mesothelin which is listed at approximately 100% but GVAX's well-hyped adjuvant couldn't rescue another in long line of failed allogeneic cancer vaccines. The deal with Aratana could get ADXS-cHER2 the first approved immunotherapy for animals in 2015. Actually a detoxified cell wall skeleton solution Ribi Immonochem was developing as an adjuvant was approved as a first line treatment by itself for treating surface tumors in horses. It was efficacious but failed in the marketplace as too much of a nuisance. When Dr. Ribi died in a crash of the plane he was piloting to a scientific conference, his first born fell into the hands of an incompetent crook who handed the technology off to another incompetent, a wildly praised idol of Seattle's Billionaire Boys Club. When the star of Seattle ran out of gas, the only item left of value was the adjuvant but I lost track of the trail. Best, Terry |
return to message board, top of board |